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Objective: The aim of this study was to analyse the diagnostic accuracy
and the clinical usefulness of combination of troponin and copeptin for rapid
rule out of non ST elevation myocardial infarction (NSTEMI) diagnosis in
Emergency Department (ED).
Method: This study was an ancillary analysis of a prospective 11 months
observational study. Consecutive patients admitted to an university ED for chest
pain within 12 hours of ED presentation and without ST elevation on a 12-lead
ECG were eligible. Blood samples for determination of copeptin were frozen
at –80°C until assayed in a blinded fashion. Patients were classified by two inde-
pendent physicians (kappa=0.72) as having acute coronary syndrome (ACS) and
NSTEMI if cTnI was above 0.1 μg/L on serial testing. Performance of combina-
tion of cTnI and copeptin for NSTEMI diagnosis at presentation was studied and
clinical utility was assessed by multivariate analysis, area under the curve (AUC)
calculation for accuracy, and reporting operating characteristics with 95% confi-
dence intervals.
Results: Out of the 641 eligible patients who were recruited, non-ST
elevation ACS was diagnosed in 180 patients (28%) including 95
NSTEMI. The negative predictive value of the combination of copeptin
and cTnI measures was 97.6% (95% CI 96.4-98.7) versus 92.8% (95%CI
90.8-94.8) with cTnI alone. The patient classification was significantly
improved when copeptin was added to the usual diagnostic tools used for
NSTEMI management: the AUC of the model with cTnI alone and with
cTnI and copeptin were 0.92 (95%CI 0.89-0.95) and 0.94 (95%CI 0.9-
0.96) respectively, p<0.05.
Conclusion: Combination of copeptin and troponin allows a rapid rule out of
NSTEMI at admission in ED and improves the early triage of patients with chest
pain.
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Aim:To evaluate the prognostic value at 6 months (m) of residual pulmo-
nary vascular obstruction (RPVO) measured at discharge in pts with inter-
mediate- or high-risk PE.
Methods: 416 consecutive pts with intermediate- or high-risk PE who
survived the acute phase were prospectively included. Pts with known
cardiopulmonary disease were excluded. Perfusion lung scans were per-
formed within 6-8 days after onset of treatment. RVPO was graded as the
proportion of lung not perfused. Primary objective was a combined end-
point at 6 m, including death, recurrent PE, appearance of signs of heart
failure (HF).
Results: At 6m, 32 patients (7.7%) had 1 adverse event: 15 deaths
(3.6%), 12 recurrent PE (2.9%), 14 cases (3.4%) of HF. Independent predic-
tors of combined endpoint were: cancer (odds ratio (OR) 4.51 [1.63-12.5]);
presence of >=1 risk factor for venous thrombo-embolic disease (OR 4.42
[1.53-12.8]); renal insufficiency at admission (OR 2.91 [1.16-7.27]); persistent
ECG signs of cor pulmonale (OR 3.2 [1.11-9.24]); and persistent echographic
signs of RV dysfunction (OR 4.99 [1.46-16.31]). Severity of RPVO at dis-
charge was significantly associated with unfavorable outcome (OR 2.56 [1.69-
3.87]). The incremental prognostic value of the RVPO information was con-
firmed by a decrease in the Akaike criterion, and increases in indices of cali-
bration and discrimination when RVPO was added to the multivariate model.
The threshold RVPO value for predicting adverse events was estimated at
35% (figure). Pts with RVPO >threshold at discharge had a significantly
higher risk of death at 6m (p=0.01).
Conclusion: RPVO evaluated before hospital discharge in pts with
intermediate- to high-risk PE is a powerful prognostic factor for outcome
at 6m. RPVO 35% is associated with an increased risk of adverse events
at 6m.
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Paroxysmal supraventricular tachycardia (SVT) is considered as benign.
The purpose of the study was to report the prevalence of SVT-related adverse
events.
Methods: 1269 patients (pt), aged from 6 to 93 years with a normal ECG
in sinus rhythm were recruited for SVT, confirmed by electrophysiological
study. Pts with anterograde conduction through accessory pathway (AP) were
excluded. SVT-related adverse events were collected.
Results: Adverse event occurs in 207 pts (16%) (group I, gr); 10 of them
had a very serious event (gr I A): resuscitated ventricular fibrillation was pro-
voked by SVT in 1 pt with coronary heart disease (HD), 1 pt with hyper-
trophic cardiomyopathy; 1 pt 55 years old, with respiratory failure, died after
a prolonged SVT. Six pts presented resuscitated cardiac arrest after anti-
arrhythmic drugs used to stop SVT (sotalol, verapamil). 197 pts presented
with a poorly-tolerated SVT (gr I B), syncope (148), acute coronary syndrome
(36), tachycardiomyopathy (6), stage IV of heart failure (5), inappropriate
shock at ICD (1), collapsus after verapamil (1). Gr I was compared to pts
without adverse events (gr II). Gr I was older than gr II (55±20 vs
49±18 years)(p<0.003). Male gender was more frequent in gr IB (53%) than
in gr II (38%) (p<0.02). Underlying HD was more frequent in gr I (32%) than
in gr II (6%) ( p<0.0000). The rate in tachycardia did not differ (183±41 bpm
in gr I, 186±35 in gr II). SVT mechanism was similar: reentry in a concealed
AP was noted in 19 % of gr I and II. Typical and atypical AV nodal reentrant
tachycardias represented other causes. In gr II, 2 ablation-related deaths in old
women and one sudden death 2 months after ablation were noted among 663
patients who had SVT ablation.
Conclusions: SVT-related adverse events occurred in 16% of patients.
Advanced age, male gender and presence of HD were predisposing factors.
However, life-threatening arrhythmias were rare and represented less than 1
%. Most of them were drug-related. 
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Aims: Due to its prolonged declining clinical effect, levosimendan might
help in weaning patients dependent on inotropes. We assessed the effect of a
24-hour infusion of levosimendan in a cohort of advanced heart failure
patients dependent on dobutamine or milrinone.
Methods: In this prospective observational study, 71 patients (pts), aged
58 [IQR: 44-63] years with advanced heart failure (28 ischaemic) and depen-
dant on inotropes (define as failure of >2 consecutive trials in 7 days; dob-
utamine n=62, milrinone n=9) were included. They received a 24-hour
intravenous infusion of levosimendan (0.1 μg/kg/min) in the ICU. 4 of them
had an intra-aortic balloon pump. Success was defined as “alive and free from
inotrope” at the end of ICU stay.
Results: The median time from hospital admission to beginning of levosi-
mendan infusion was 16 [IQR:5.5-29.2] days. Fifty five pts (76.1%) were
alive and free of dobutamine or milrinone 48H after initiation of levosim-
endan. Four patients failed to receive the full levosimendan amount and
9 patients (16%) had to receive norepinephrine because of hypotension. Atrial
fibrillation occurred in 9 pts (12.7%). Median time to stop dobutamine or mil-
rinone was 18 [IQR:4.5-24] hours. Reinitiation of inotropes was needed in
3 pts.
